Calcipotriol and corticosteroids, two therapy modalities frequently prescribed in the treatment of psoriasis, are often used in combination. The aim of the present study was to determine whether the cell biological response pattern of concurrent use of calcipotriol and corticosteroids is different from calcipotriol monotherapy. Forty patients with chronic plaque psoriasis were divided at random in A statistically significant decrease of the percentage of basal cells in S-and C^M-phase (prolifera tion) was obtained with all therapy modalities, except for calcipotriol monotherapy applied once daily. A significant reduction of the number of vimentin-positive cells (non-keratinocytes) was observed following combined treatment with calcipotriol and clobetasone butyrate. In contrast, monotherapy with calcipotriol had virtually no effect on the number of vimentin-positive cells.
Vitamin D j analogues interfere with various c istics of the psoriatic plaque: epidermal tion, impaired differentiation and cutaneous mation.
In vitro studies demonstrated that c inhibits proliferation and stimulates differentiation in cultured human keratinocytes. Several inflammatory are modulated by calcipotriol.1"5 In processes VIVO, topical application of calcipotriol to psoriatic plaques resulted in decreased epidermal DNA synthesis and a shift of the expression pattern of epidermal cytokeratins towards normalization.6' 9 Furthermore, calcipotriol 1 0 has been reported to influence different cytokines and to change the numbers of several immunocytes (polymorphonuclear leucocytes, CD la positive cells, T s) in psoriatic plaques.8,9,11,12 epidermal proliferation has been reported to be the most conspicuous effect of treatment, whereas interference with inflammation is less marked.9 Using absolute counts, however, a sig nificant reduction of infiltrate cells in the epidermis has been claimed.8 In this respect it is of relevance that the combination of topical treatment with calcipotriol and low-dose systemic cyclosporin (2 mg/kg per day) proved to be a highly effective combination, indicating that the immunomodulating effect of cyclosporin might comrelatively low immunosuppressive capacity of calcipotriol in vivo.1* Double-blind, placebo-controlled studies showed that (c ) 
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Flow cytometric analysis
The flow cytometric measurements and analysis were performed before the treatment codes were revealed. In the present study the effect of the different treatment schedules was assessed using flow cytometric quantilication of epidermal growth, and of markers fol iation and inflammation. These markers were chosen in analogy to the clinical features of the psoriatic lesion, i.e. erythema, induration and desquamation that are assessed in the PASI score. In previous studies the methodology was evaluated in epidermal hyperpro liferation induced by sellotape stripping,2(1 after application of leukotriene B4 to normal skin 27 and in psoriatic patients before and following treatment. In conclusion, the present flow cytometric study lends sis that the effect of calcipotriol once daily is inferior to calcipotriol twice daily and that the combination of calcipotriol and a corticosteroid has a better antipsoriatic efficacy compared with calcipotriol monotherapy. 
